Key result
In patients with intracranial hemorrhage on Factor Xa inhibitors, andexanet alfa improved hemostatic efficacy versus usual care but increased ischemic strokes.
Why the study?
Does andexanet alfa improve hemostatic efficacy in patients with acute intracranial hemorrhage receiving an oral Factor Xa inhibitor compared to usual care?
Does andexanet alfa improve hemostatic efficacy in patients with acute intracranial hemorrhage receiving an oral Factor Xa inhibitor compared to usual care?
Answers are grounded in this paper and cite their sources.
While andexanet alfa improves radiological hemostatic efficacy in DOAC-associated intracranial hemorrhage, the lack of demonstrable benefit on clinical outcomes like death or disability, combined with a significant increased risk of stroke, highlights substantial uncertainty regarding its net clinical benefit.
Andexanet Alfa in Acute Intracranial Hemorrhage in Patients Receiving an Oral Factor Xa Inhibitor (ANNEXA-I), the first ever randomized controlled trial of a reversal agent for direct oral anticoagulants, was published in 2024. The trial, which randomized patients with intracranial hemorrhage to andexanet alfa or usual care, was mandated by the United States Food and Drug Administration as part of its conditional approval in 2018. This approval was originally based on the single-arm trial, The Andexanet Alfa, a Novel Antidote to the Anticoagulation Effects of Factor Xa Inhibitors (ANNEXA-4). ANNEXA-I was stopped early for benefit and showed a reduction in the number of patients with significant hematoma expansion. However, the study was not powered for clinical endpoints such as disability or death and showed no difference in these outcomes. It did, however, show an increased risk of thrombosis, predominantly stroke with andexanet alfa. In this perspective, I reflect on some of the key criticisms of the trial and the implications for its interpretation.
No takes yet. Share an insight, caveat, or question.
Richard J. Buka (2024) conducted an editorial in Acute Intracranial Hemorrhage in Patients Receiving an Oral Factor Xa Inhibitor (n=530). Andexanet alfa vs. Usual care (physician's choice, predominantly 4-factor prothrombin complex concentrate) was evaluated on Hemostatic efficacy (hematoma volume expansion ≤35%, NIHSS increase <7, and no rescue therapy at 12 hours) (p=0.003). In patients with intracranial hemorrhage on Factor Xa inhibitors, andexanet alfa improved hemostatic efficacy versus usual care but increased ischemic strokes.
Synapse has enriched 10 related papers. Consider them for comparative context: